Hologic (NASDAQ:HOLX) Reaches New 1-Year Low - Here's What Happened

Hologic, Inc. (NASDAQ:HOLX - Get Free Report)'s stock price hit a new 52-week low on Monday . The stock traded as low as $55.89 and last traded at $57.17, with a volume of 6818925 shares changing hands. The stock had previously closed at $56.50.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on HOLX shares. Evercore ISI dropped their price target on shares of Hologic from $76.00 to $73.00 and set an "in-line" rating on the stock in a research note on Thursday, February 6th. Raymond James reiterated an "outperform" rating and set a $90.00 price target (down previously from $95.00) on shares of Hologic in a report on Thursday, February 6th. Leerink Partners lowered shares of Hologic from an "outperform" rating to a "market perform" rating and decreased their price objective for the stock from $80.00 to $75.00 in a report on Thursday, February 6th. William Blair reiterated an "outperform" rating on shares of Hologic in a research note on Thursday, February 6th. Finally, Leerink Partnrs cut Hologic from a "strong-buy" rating to a "hold" rating in a research note on Thursday, February 6th. Eleven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $84.62.

Hologic Trading Down 0.5 %

The stock has a 50-day moving average price of $61.14 and a two-hundred day moving average price of $70.22. The stock has a market capitalization of $13.02 billion, a PE ratio of 18.30, a PEG ratio of 2.14 and a beta of 0.82. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, equities analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hedge Funds Weigh In On Hologic

A number of hedge funds have recently made changes to their positions in HOLX. Barclays PLC grew its holdings in Hologic by 47.6% during the 3rd quarter. Barclays PLC now owns 718,231 shares of the medical equipment provider's stock valued at $58,507,000 after buying an additional 231,578 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new position in shares of Hologic during the third quarter worth $93,000. Tidal Investments LLC grew its stake in Hologic by 60.1% during the third quarter. Tidal Investments LLC now owns 15,351 shares of the medical equipment provider's stock valued at $1,250,000 after acquiring an additional 5,764 shares in the last quarter. Franklin Resources Inc. increased its holdings in Hologic by 171.7% in the 3rd quarter. Franklin Resources Inc. now owns 278,295 shares of the medical equipment provider's stock valued at $22,714,000 after acquiring an additional 175,855 shares during the last quarter. Finally, Oddo BHF Asset Management Sas purchased a new stake in Hologic in the 3rd quarter worth $1,110,000. Institutional investors own 94.73% of the company's stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.